17. The Future: What's in the Toolkit for Prostate Cancer Diagnosis and Treatment?

  1. Ashutosh K. Tewari M.D., M.Ch.2,
  2. Peter Whelan MS, FRCS3 and
  3. John D. Graham FRCP, FRCR4
  1. Norman J. Maitland

Published Online: 24 JAN 2014

DOI: 10.1002/9781118347379.ch17

Prostate Cancer: Diagnosis and clinical management

Prostate Cancer: Diagnosis and clinical management

How to Cite

Maitland, N. J. (2014) The Future: What's in the Toolkit for Prostate Cancer Diagnosis and Treatment?, in Prostate Cancer: Diagnosis and clinical management (eds A. K. Tewari, P. Whelan and J. D. Graham), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9781118347379.ch17

Editor Information

  1. 2

    Ronald P. Lynch Professor of Urologic-Oncology, Director, Center for Prostate Cancer, Weill Cornell Medical College and New York Presbyterian Hospital, Director, LeFrak Center of Robotic Surgery, NYPH, Weill Cornell Medical College, New York Presbyterian Hospital, New York, USA

  2. 3

    Community Urologist, Leeds, UK, Emeritus Consultant Urological Surgeon, Pyrah Department of Urology, St. James's University Hospital, Leeds, UK

  3. 4

    Consultant in Clinical Oncology, Beacon Centre, Musgrove Park Hospital, Taunton, Somerset, UK, Director, National Collaborating Centre for Cancer, Cardiff, UK

Author Information

  1. Department of Biology, YCR Cancer Research Unit, University of York, Heslington, York, UK

Publication History

  1. Published Online: 24 JAN 2014
  2. Published Print: 6 FEB 2014

ISBN Information

Print ISBN: 9781118347355

Online ISBN: 9781118347379



  • prostate cancer;
  • molecular biology;
  • genetics;
  • stem cells;
  • treatment resistance


Faced with an increasingly successful diagnostic regimen for prostate cancer and an ageing population, it is important that the basic science laboratory provides a regular flow of new technology to augment the clinicans’ armory of weapons to treat the disease. However, the number of new patients also places an increased focus on not only correct diagnosis, but also the decision about whom to treat, in the face of overtreatment implications. I wish to argue that the most sophisticated new treatments are being developed in biological systems which are more than 30 years old: a good drug performs exactly the same in an inadequate test as a bad drug in a patient. Hence we may have to reconsider not only treatment strategies, but also the patient population we wish to treat to make the most of new developments from the laboratory.